1594-58-7

Basic information

• Product Name: 3-PYRIDYLAMIDOXIME
• Synonyms: N-HYDROXYNICOTINAMIDINE;N'-HYDROXYPYRIDINE-3-CARBOXIMIDAMIDE;RARECHEM BG FB 0128;PYRIDINE-3-CARBOXAMIDE OXIME;AKOS B030080;3-PYRIDYLAMIDOXIME;3-PYRIDINECARBOXAMIDOXIME;BUTTPARK 33\04-45
• CAS NO: 1594-58-7
• Molecular Formula: C₆H₇N₃O
• Molecular Weight: 137.14
• Product Categories: pharmacetical;Pyridines
• Mol File: 1594-58-7.mol

Chemical Properties

• Melting Point: 130-135 °C(lit.)
• Boiling Point: 350 °C at 760 mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.31 g/cm³
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 13.22±0.50(Predicted)
• CAS DataBase Reference: 3-PYRIDYLAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRIDYLAMIDOXIME(1594-58-7)
• EPA Substance Registry System: 3-PYRIDYLAMIDOXIME(1594-58-7)

Safety Data

• Hazard Codes: Xi,C
• Statements: 36/37/38-34
• Safety Statements: 26-36-37/39-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1594-58-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3-Pyridylamidoxime is used as a chemical intermediate for the synthesis of various compounds, including 3-(3-pyridyl)-5-trichloromethyl-1,2,4-oxadiazole. This application is significant in the development of new chemical entities with potential applications in different fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Pyridylamidoxime may serve as a key component in the development of new drugs, particularly those targeting the central nervous system or other therapeutic areas. Its unique structure and reactivity make it a promising candidate for drug design and synthesis.
Used in Research and Development:
3-Pyridylamidoxime is also used in research and development settings, where it can be employed to study the properties and reactions of various chemical compounds. Its synthesis and application in different chemical reactions can provide valuable insights into the development of new materials and technologies.

InChI:InChI=1/C6H7N3O/c7-6(9-10)5-2-1-3-8-4-5/h1-4,10H,(H2,7,9)

Upstream product

• 100-54-9 pyridine-3-carbonitrile 
• 626-55-1 3-Bromopyridine 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 154345-82-1 (D,L)-5-(2-phenyl-1-tert-butyloxycarbonylaminoethyl)-3-(3-pyridyl)-1,2,4-oxadiazole 
• 163719-72-0 ethyl [3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]carboxylate 
• 1198-99-8 3-<3>Pyridyl-4,5-dihydro-1.2.4-oxadiazolon-(5) 
• 913830-15-6 3-(3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 
• 1166828-90-5 3-{5-[1-(2-fluorophenyl)-5-pyridin-4-yl-1H-1,2,3-triazol-4-yl]-1,2,4-oxadiazol-3-yl}pyridine 
• 1166829-00-0 3-{5-[1-(2-fluorophenyl)-5-(methoxymethyl)-1H-1,2,3-triazol-4-yl]-1,2,4-oxadiazol-3-yl}pyridine 
• 1166828-98-3 3-{5-[1-(2-fluorophenyl)-5-(2-methoxyethyl)-1H-1,2,3-triazol-4-yl]-1,2,4-oxadiazol-3-yl}pyridine 
• 712334-20-8 3-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-yl}-pyridine 
• 1332498-60-8 4-[2-(3-pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-vinyl]-benzene-1,2-diol 
• 727364-75-2 C₁₇H₁₇N₃O₄ 
• 15328-03-7 5-(chloromethyl)-3-(pyridin-3-yl)-1,2,4-oxadiazole 
• 1401223-17-3 N-isopropyl-N-((3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)-2-(p-tolyloxy)acetamide 
• 1401223-40-2 (S)-N-isopropyl-N-((3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)methyl)-2-(p-tolyloxy)propanamide 
• 1401223-41-3 (R)-N-isopropyl-N-((3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)methyl)-2-(p-tolyloxy)propanamide 

Relevant articles and documents

Reactions of pentafluoropyridine with amidoximes

Abstract: In this paper, site reactivity of amidoximes with pentafluoropyridine under basic conditions in dry CH3CN was investigated. The aromatic nucleophilic substitution of pentafluoropyridine with amidoximes occurs in the 4-position of the

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

The docking approach for the screening of designed small molecule ligands, led to the identification of a critical arginine residue in peptide deformylase for spiro cyclopropyl PDF inhibitor's extra hydrophobic binding, providing us a useful tool for searching more efficient PDF inhibitors to fight for horrifying antibiotics resistance. Further synthetic modification was undertaken to optimize the potency of amide compounds. To lower metabolic susceptibility and in turn reduce unwanted metabolic toxicity that was observed clinically, while retaining desired antibacterial activity, the use of azoles as amide bioisosteres had also been investigated. After the completion of chemical synthesis, all the compounds were evaluated through in vitro antibacterial activity assay, some of which were further subject to in vivo rat pharmacokinetic assessment. Those findings in this letter showed that spiro cyclopropyl proline N-formyl hydroxylamines, and especially the bioisosteric azoles, can represent a promising class of PDF inhibitors.

Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents

Abstract In our study, three series of hydroxamate, 2-aminobenzamide, and trifluoromethyl ketone analogues have been designed and synthesized. The synthesized compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against three human cancer cell lines including A549, NCI-H661, and U937. Most analogues exhibited higher antiproliferative activities against human acute myeloid leukemia cell U937 than the other two human lung cancer cell lines. Furthermore, the compounds were examined against HDAC1, 2, and 8 isoforms. Docking study of compounds 6h, 9b, and 10a suggested that they might bind tightly to the binding pocket of HDAC2 and/or HDAC8. The results suggest that these compounds might have potential as lead compounds for the development of anti-tumor drugs with HDACs inhibitory activities.

Novel benzimidazole-oxadiazole hybrid molecules as promising antimicrobial agents

In the present study, we describe the design and expeditious synthesis of novel 2-aryl-5-(3-aryl-[1,2,4]-oxadiazol-5-yl)-1-methyl-1H-benzo[d]imidazole hybrid molecules as promising antimicrobial agents. The core moiety 2-aryl-ethyl-1H-benzo[d]imidazole-5-

SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure also relates to a method of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) a method of treating cancer, and a method of inhibiting USP28, comprising administering to a subject in need thereof a compound of formula (I).

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Entry into (E)-3-(1,2,4-oxadiazol-5-yl)acrylic acids via a one-pot ring-opening/ring-closing/retro-Diels-Alder reaction sequence

A simple and convenient one-pot method is reported for the synthesis of (E)-3-(3-aryl(heteroaryl, alkyl)-1,2,4-oxadiazole-5-yl)acrylic acids utilizing readily accessible or commercially available substituted benzamidoximes and inexpensive exo-3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride. The method is based on the reaction of amidoximes with the anhydride in a basic medium at RT followed by an acid-catalyzed retro-Diels-Alder reaction. The observed stereoselective heterocyclization/retro-Diels-Alder cascade process is suitable for the synthesis of a wide range of substituted (E)-1,2,4-oxadiazole-5-ylacrylic acids featuring electron donating and electron withdrawing groups on the aryl moiety, as well as heteroaryl or alkyl substituents at position 3 of the 1,2,4-oxadiazole ring (42–79%; 15 examples).

Synthesis and Evaluation of Antibacterial Activity of 1,2,4-Oxadiazole-Containing Biphenylcarboxylic Acids

Abstract: A one-pot method for the synthesis of biphenylcarboxylic acids containing 1,2,4-oxadiazole ring in the NaOH–DMSO system was developed. The results of in vitro experiments showed that the synthesized compounds exhibit antibacterial activity against susceptible strains of E. coli and S. aureus.

5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein

The HIV-1 nucleocapsid (NC) protein is a small basic DNA and RNA binding protein that is absolutely necessary for viral replication and thus represents a target of great interest to develop new anti-HIV agents. Moreover, the highly conserved sequence offers the opportunity to escape the drug resistance (DR) that emerged following the highly active antiretroviral therapy (HAART) treatment. On the basis of our previous research, nordihydroguaiaretic acid 1 acts as a NC inhibitor showing moderate antiviral activity and suboptimal drug-like properties due to the presence of the catechol moieties. A bioisosteric catechol replacement approach led us to identify the 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new class of HIV-1 NC inhibitors. Hit validation efforts led to the identification of optimized analogs, as represented by compound 28, showing improved NC inhibition and antiviral activity as well as good ADME and PK properties.

Pharmaceutical application of indole alkaloids and derivatives thereof

The invention discloses pharmaceutical application of indole alkaloids and derivatives thereof, belonging to the field of medicinal chemistry, pharmacology and preparations. The invention specificallyrelates to application of vinpocetine derivatives in treatment or prevention of diseases, cerebral arteriosclerosis, hypertension, hemorrhagic stroke sequelae, hyperviscosity and cerebral ischemia caused by ischemic cerebrovascular lesions, and application of the vinpocetine derivatives in preparation of a cerebrovascular dilator, a composition for improving ischemic cerebrovascular lesions and peripheral blood supply and a composition for improving the utilization rate of cerebral blood oxygen.